NOVO.B.DK

373.75

+0.08%↑

COLO.B.DK

566

-0.81%↓

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505

-0.82%↓

AMBUB.DK

106.2

+2.21%↑

NOVO.B.DK

373.75

+0.08%↑

COLO.B.DK

566

-0.81%↓

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505

-0.82%↓

AMBUB.DK

106.2

+2.21%↑

NOVO.B.DK

373.75

+0.08%↑

COLO.B.DK

566

-0.81%↓

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505

-0.82%↓

AMBUB.DK

106.2

+2.21%↑

NOVO.B.DK

373.75

+0.08%↑

COLO.B.DK

566

-0.81%↓

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505

-0.82%↓

AMBUB.DK

106.2

+2.21%↑

NOVO.B.DK

373.75

+0.08%↑

COLO.B.DK

566

-0.81%↓

HLUNB.DK

45.28

-0.09%↓

ZEAL.DK

505

-0.82%↓

AMBUB.DK

106.2

+2.21%↑

Search

Genmab A-S

Abrir

2,085 2.46

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2026

Máximo

2091

Indicadores-chave

By Trading Economics

Rendimento

228M

423M

Vendas

210M

925M

P/E

Médio do Setor

14.812

35.739

EPS

34.77

Margem de lucro

45.73

Funcionários

2,639

EBITDA

448M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-1.49% downside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

26B

113B

Abertura anterior

2082.54

Fecho anterior

2085

Genmab A-S Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de ago. de 2025, 15:10 UTC

Grandes Movimentos do Mercado

Genmab Shares Rise After Positive Results for Epcoritamab Trial

10 de mar. de 2025, 15:16 UTC

Grandes Movimentos do Mercado

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

10 de dez. de 2024, 07:05 UTC

Conversa de Mercado

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparação entre Pares

Variação de preço

Genmab A-S Previsão

Preço-alvo

By TipRanks

-1.49% parte inferior

Previsão para 12 meses

Média 2,493.35 DKK  -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Genmab A-S - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

7 ratings

3

Comprar

2

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat